Delcade Avocats & Solicitors, took part in the sale of the entire capital of RAL Diagnostics to CELLAVISION AB
On October 21, 2019 By Sabine VANDERSTRICHT
Paris, October 20, 2019 – Delcade Avocats & Solicitors, took part in the sale of the entire capital of RAL Diagnostics to CELLAVISION AB (Publ).
Delcade Avocats & Solicitors (Sophie Coignat, partner and Pierre Papelard, partner) advised the shareholders of the company RAL Diagnostics, a French company specializing in biological dyes in the medical and industrial sector, in the context of the sale of their shares in RAL Diagnostics to CellaVision AB (Publ), a Swedish listed company specializing in the medical technology sector, for an enterprise value of € 25 million.
RAL Diagnostics is positioned as a key player in the field of health and contributes to the innovation of In Vitro Diagnostics (IVD) by creating more efficient and environmentally friendly products.
CellaVision AB (Publ) was advised by FTPA Avocats (Nathalie Younan, partner, Johanna Grangier, associate) and the Swedish law firm Mannheimer Swartling (Per Asbrink, partner, Erik Hensfelt, associate)
Our latest news
Coordination of pension schemes: what legal framework applies to international careers?
International workforce mobility involves a complex interplay between several national social security systems. In terms of retirement, this raises major legal questions: which legislation applies to a posted or expatriate employee? How are their acquired rights preserved from one country to another? Under what terms will their pension ultimately be settled? These are questions our […]
Read
Shadow Payroll and International Assignments in France: a compliance guide for foreign employers
Foreign companies deploying employees or executives to France face a layered set of obligations that span employment law, payroll reporting, taxation, social security coordination, and immigration procedures. Managing these requirements in isolation — through separate providers across different jurisdictions — often leads to gaps, duplications, or costly errors. DELCADE’s International Assignment Services practice offers a […]
Read
DELCADE advises Geistlich Pharma AG on taking control of OST Développement
The European regenerative medicine market continues to consolidate. On 24 April 2026, the Swiss group Geistlich Pharma AG completed the acquisition of a majority stake in OST Développement, a French specialist in bone regeneration. DELCADE acted as legal counsel to the acquirer, extending a collaboration that began back in 2024. A two-stage M&A move The […]
Read